Up 58% YTD, is Eli Lilly Stock Still a Buy?

Valued at $876.3 billion, Eli Lilly & Co. (LLY) is a mega-cap pharmaceutical company that focuses on creating and distributing groundbreaking treatments for obesity, diabetes, cancer, immunological disorders, and neurological conditions. Dedicated to enhancing patient health, Eli Lilly utilizes advanced biotechnology and genetic medicine to tackle some of the most critical health issues globally. With operations across the globe, LLY is headquartered out of Indianapolis.

LLY stock has been on a tear over the past year, driven by the blockbuster success of its Type II diabetes and obesity drugs, marketed as Mounjaro and Zepbound, respectively. LLY is up 68.6% over the past 52 weeks, and the shares have gained 58% on a YTD basis.